All Outputs (2)

The treatment of mild upper respiratory tract infections – a position paper with recommendations for best practice (2023)
Journal Article
Smith, A., Kardos, P., Pfaar, O., Randerath, W., Estrada Riolobos, G., Braido, F., & Sadofsky, L. (2023). The treatment of mild upper respiratory tract infections – a position paper with recommendations for best practice. Drugs in Context, 12, Article 2023-4-2. https://doi.org/10.7573/dic.2023-4-2

Following the waning severity of COVID-19 due to vaccination and the development of immunity, the current variants of SARS-CoV-2 often lead to mild upper respiratory tract infections (MURTIs), suggesting it is an appropriate time to review the pathog... Read More about The treatment of mild upper respiratory tract infections – a position paper with recommendations for best practice.

Ingredients of Vicks VapoRub inhibit rhinovirus-induced ATP release (2023)
Journal Article
Stinson, R. J., Morice, A. H., Ahmad, B., & Sadofsky, L. R. (2023). Ingredients of Vicks VapoRub inhibit rhinovirus-induced ATP release. Drugs in Context, 12, 1-18. https://doi.org/10.7573/dic.2023-3-2

Background: Over-the-counter therapies, such as Vicks VapoRub, are frequently used in the management of upper respiratory tract infection symptoms. Of these, acute cough is the most bothersome; however, the mechanisms involved have not been fully elu... Read More about Ingredients of Vicks VapoRub inhibit rhinovirus-induced ATP release.